[go: up one dir, main page]

MX2009003301A - Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas. - Google Patents

Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.

Info

Publication number
MX2009003301A
MX2009003301A MX2009003301A MX2009003301A MX2009003301A MX 2009003301 A MX2009003301 A MX 2009003301A MX 2009003301 A MX2009003301 A MX 2009003301A MX 2009003301 A MX2009003301 A MX 2009003301A MX 2009003301 A MX2009003301 A MX 2009003301A
Authority
MX
Mexico
Prior art keywords
nimiv
rhinovirus
vaccine applications
novel neutralizing
neutralizing immunogen
Prior art date
Application number
MX2009003301A
Other languages
English (en)
Inventor
Kirill Kalnin
Yanhua Yan
Harold Kleanthous
Original Assignee
Sanofi Pasteur Biologics Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Co filed Critical Sanofi Pasteur Biologics Co
Publication of MX2009003301A publication Critical patent/MX2009003301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a métodos y composiciones para prevenir o tratar infección de rhinovirus humano.
MX2009003301A 2006-09-29 2007-10-01 Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas. MX2009003301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84845106P 2006-09-29 2006-09-29
PCT/US2007/021053 WO2008057158A2 (en) 2006-09-29 2007-10-01 Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications

Publications (1)

Publication Number Publication Date
MX2009003301A true MX2009003301A (es) 2009-07-15

Family

ID=39364960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003301A MX2009003301A (es) 2006-09-29 2007-10-01 Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.

Country Status (12)

Country Link
US (2) US8652486B2 (es)
EP (2) EP2066343B1 (es)
JP (1) JP2010504759A (es)
KR (1) KR20090092764A (es)
CN (1) CN101678095B (es)
AU (1) AU2007318206A1 (es)
BR (1) BRPI0719443A2 (es)
CA (1) CA2664628C (es)
IL (1) IL197755A (es)
MX (1) MX2009003301A (es)
WO (1) WO2008057158A2 (es)
ZA (1) ZA200901993B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100290A2 (en) * 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
US20110091501A1 (en) * 2008-03-27 2011-04-21 Sanofi Pasteur Biologics Co. Recombinant Rhinovirus Vectors
EP2316481A1 (en) 2009-10-30 2011-05-04 Biomay Ag Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
GB201115910D0 (en) 2011-09-14 2011-10-26 Univ Manchester Peptides
EP3608332B1 (en) 2013-03-15 2022-06-01 GlaxoSmithKline Biologicals SA Vaccine against human rhinovirus
HK1220700A1 (zh) 2013-03-15 2017-05-12 Biological Mimetics, Inc. 免疫原性人鼻病毒(hrv)的组合物
US11160857B2 (en) * 2015-06-15 2021-11-02 Emory University Multivalent enterovirus vaccine compositions and uses related thereto
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0169146A3 (en) 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
JPS6147191A (ja) * 1984-07-20 1986-03-07 メルク　エンド　カムパニー　インコーポレーテッド ヒト・ライノウイルスｒｎａおよびたんぱく
US5541100A (en) * 1990-09-12 1996-07-30 Rutgers University Chimeric rhinoviruses
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20040146524A1 (en) 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
US7429472B2 (en) * 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
WO2006037070A2 (en) * 2004-09-28 2006-04-06 Alza Corporation Stabilization of alum-adjuvanted immunologically active agents
US8153760B2 (en) * 2005-01-19 2012-04-10 Donald Danforth Plant Science Center Rhinovirus vaccines

Also Published As

Publication number Publication date
EP2066343B1 (en) 2017-06-14
IL197755A0 (en) 2011-08-01
CN101678095A (zh) 2010-03-24
BRPI0719443A2 (pt) 2013-12-10
WO2008057158A3 (en) 2008-08-07
US8652486B2 (en) 2014-02-18
JP2010504759A (ja) 2010-02-18
WO2008057158A2 (en) 2008-05-15
CA2664628C (en) 2016-08-09
IL197755A (en) 2015-09-24
CN101678095B (zh) 2013-04-24
EP2066343A4 (en) 2010-05-19
ZA200901993B (en) 2010-07-28
US9381237B2 (en) 2016-07-05
EP2548573A1 (en) 2013-01-23
KR20090092764A (ko) 2009-09-01
AU2007318206A2 (en) 2009-06-04
AU2007318206A1 (en) 2008-05-15
US20100297169A1 (en) 2010-11-25
WO2008057158A9 (en) 2008-09-18
US20140161833A1 (en) 2014-06-12
CA2664628A1 (en) 2008-05-15
EP2066343A2 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
MX2009003301A (es) Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.
IN2012DN00971A (es)
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
PL2126049T3 (pl) Przeciwciała przeciwko ludzkiemu wirusowi cytomegalii (HCMV)
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
MX2010005244A (es) Composiciones y métodos para la terapia y el diagnóstico de influenza.
IN2012DN00624A (es)
EA200970529A1 (ru) Антивирусная композиция и способ ее применения
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
UA100507C2 (ru) Предупреждение и лечение субклинической формы болезней, вызываемых цирковирусом свиней (pcvd)
PH12012501308A1 (en) Binding members for human cytomegalovirus
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
MX2011008649A (es) Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EA200870584A1 (ru) Пролекарства пенема
TN2012000217A1 (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
IL198202A0 (en) Peptide-cytotoxic conjugates
MX2009003751A (es) Proteina ipad de shigella y su uso como vacuna contra infeccion por shigella.
PH12012500933A1 (en) Actinobacillus suis antigens
PT2059532E (pt) Moléculas de ligação humanas capazes de neutralizar o vírus da gripe h5n1 e seus usos

Legal Events

Date Code Title Description
HH Correction or change in general